Altimmune Inc

-0.12 (-1.01%)
Products, Regulatory, Other Pre-Announcement

Altimmune Inc Announces Initiation Of 12-Week Phase 1B Trial Of Pemvidutide

Published: 10/04/2021 11:55 GMT
Altimmune Inc (ALT) - Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects With Non-alcoholic Fatty Liver Disease.
Altimmune Inc - Pemvidutide Was Well-tolerated Without Need for Dose Titration, and No Discontinuations Due to Adverse Events Were Reported.
Altimmune Inc - Study is Expected to Read Out Topline Results in First Half of 2022.
Altimmune Inc - Based on Findings of Nafld Study, Company Intends to Initiate a 52-week Biopsy Driven Phase 2 Nash Study in 2022.
Altimmune Inc - Intends to File a Second Ind Application in Obesity in 2021 With Plans to Initiate a 48-week, Phase 2 Obesity Trial in H1 2022.